US EditionLate-Breaking Analysis Demonstrates Characteristics Associated with Long-Term Overall Survival ...
- Novocure shared findings from the Phase 3 PANOVA-3 study conducted in Baar, Switzerland, demonstrating that Tumor Treating Fields therapy, combined with chemotherapy, significantly extended overall survival in patients with locally advanced pancreatic cancer that cannot be surgically removed.
- The trial tested TTFields therapy combined with gemcitabine and nab-paclitaxel after pancreatic cancer treatment options remained limited for inoperable cases.
- Patients receiving TTFields had a median overall survival of 16.2 months versus 14.2 months with chemotherapy alone, alongside longer pain-free survival and maintained quality of life.
- The median overall survival improvement was 2.0 months with a hazard ratio of 0.82 and a statistically significant p-value of 0.039 as reported by lead investigator Vincent Picozzi.
- Novocure plans to submit data to the FDA in late 2025 to support regulatory approval, suggesting TTFields could become a standard treatment for this challenging cancer.
14 Articles
14 Articles
Late-breaking analysis demonstrates characteristics associated with long-term overall survival ...
Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic adenocarcinoma1Post-hoc analysis of NAPOLI 3 study determined characteristics associated with long-term survival, with median overall survival of 19.5 months amongst…
ParrySound.com
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic adenocarcinoma1Post-hoc analysis of NAPOLI 3 study determined characteristics associated with long-term survival, with median overall survival of 19.5 months amongst…
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde regimen in metastatic pancreatic adenocarcinoma
Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic adenocarcinoma1 Post-hoc analysis of NAPOLI 3 study determined characteristics associated with long-term survival, with median overall survival of 19.5 months amongst long-term survivors receiving Onivyde® plus oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) regimen as a first-line […]
Coverage Details
Bias Distribution
- 82% of the sources lean Left
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
